Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

• Status: Completed
• Trial end date: 2017-03-29
• Target enrollment: 0
• Participant gender: All

Summary

This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days. The study will include 100 patients treated in different public centers in the Mexican Republic.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Dasatinib

Criteria

Inclusion Criteria:

• Men and women ≥15 years of age

• Diagnosis of chronic myeloid leukemia in any phase that used dasatinib at any time between January 2008 and November 2014

• Have received dasatinib as part of their first-line or second-line treatment for at least 45 days

Exclusion Criteria:

• Patients who received dasatinib as part of any clinical trial

• Patients who do not have complete data on the data collection sheet

• Patients who do not have medical records available at the moment of the data verification